APAC Peptide Therapeutics Market

APAC Peptide Therapeutics Market Size (2023 to 2028)

The size of the Asia-pacific peptide therapeutics market is estimated to be growing at a CAGR of 9.96% from 2023 to 2028.

The growing patient population suffering from chronic diseases such as cancer, cardiovascular diseases, metabolic diseases, and diabetes in the APAC region is one of the key factors propelling the growth of the peptide therapeutics market in APAC. Cancer is one of the leading causes of the increasing death rate in the region. Chemotherapy and radiation therapy are some of the most popular known therapies to the population. To overcome some of the complications in chemotherapy, healthcare providers suggest that cancer patients take a peptide-based drug that is less toxic and easier to synthesize.

The growing geriatric population in APAC is another notable factor boosting the growth of the APAC peptide therapeutics market. The older population prefers therapeutic peptides for diabetes, gastric, and heart-related diseases. Peptide drugs help treat diabetes mellites in all age groups of people suffering from different types of diabetes. As per a recent study, nearly 60 percent of the Asian population is suffering from diabetes. Oral drugs have become famous for diabetes because they are more convenient than injections.

The growing number of advancements in developing novel peptide therapeutics drugs favors the growth of the APAC peptide therapeutics market. Peptide drug development has a tremendous growth opportunity during the forecast period due to the manufacturing of new peptides and analytic technologies. These peptides are produced by modifying chemical and biological methods, and researchers are finding a new way to design a drug that overcomes the drawbacks of the existent peptides. Advanced technologies such as AI technologies are used in the development of a peptide which helps in increasing the speed of the development with fewer errors. Additionally, increasing clinical trials also help the market development. Clinical trials help eliminate any drawbacks during drug manufacturing, which helps reduce the investment in manufacturing these drugs. The researcher also focuses on manufacturing different kinds of drugs, such as oral drugs, by using nanoparticles and injection drugs.

On the other hand, high costs associated with developing peptide drugs are the primary restraint to market growth. Drug approvals, lack of awareness about peptide therapeutics, lack of reimbursement policies, and strict government regulations further hinder the market’s growth rate.

This research report on the APAC peptide therapeutics market has been segmented and sub-segmented into the following categories:

By Type:

• Generic
• Innovative

By Application:

• Metabolic
• Cardiovascular Disorder
• Respiratory
• GIT
• Anti-infection
• Pain
• Dermatology
• CNS
• Renal
• Others

By Type of Manufacturers:

• In-house
• Outsourced

By Route of Administration:

• Parenteral Route
• Oral Route
• Pulmonary
• Mucosal
• Others

By Synthesis Technology:

• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

The APAC market is one of the most lucrative regional markets for peptide therapeutics worldwide. It is predicted to grow at a notable CAGR during the forecast period owing to the increasing healthcare expenditure and growing adoption of peptide therapies for various types of disorders, the rising number of pharmaceutical companies for the manufacturing of peptide therapeutics and an increasing awareness programs by the government and healthcare organizations about the availability of various peptide therapeutic drugs and the benefits of these drugs.

China held the major share of the APAC market in 2022 and is expected to register a healthy CAGR during the forecast period owing to the growing number of peptide companies in China.

India is predicted to occupy a notable share of the APAC market during the forecast period owing to the increasing number of manufacturers and suppliers and increasing investment by many key players in peptide drugs. India conducted several peptide research programs across the country in recent years and the Indian government reacted favorably to the R&D of peptide drugs.

Japan is estimated to witness a promising CAGR during the forecast period. The growth of the Japanese market is driven by the increasing approvals of advanced medicines. Researchers in Japan are showing interest in manufacturing different forms of peptides that help develop the peptide therapeutic market. Peptides play a significant role in various peptide drugs with slight modifications leading to market growth.

KEY MARKET PLAYERS:

Eli Lilly and Company, Amgen, Inc., Pfizer, Inc., Bristol-Myers Squibb Company, Ever Neuro Pharma GmbH, Takeda Pharmaceutical Company Limited, AstraZeneca PLC, GlaxoSmithKline plc, Novo Nordisk A/S., Novartis AG, Zealand Pharma AG, AmbioPharm Inc., Bachem Holding AG, PolyPeptide Group, Sanofi SA, Amylin Pharmaceuticals, CirclePharma, Inc., PeptiDream Inc., Apitope Technology, Arch NioPartners, and Galena Biopharmaceuticals are some of the noteworthy participants in the APAC peptide therapeutics market profiled in this report.